Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focusing on rare disease therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company's management will be available for one-on-one meetings on September 9th and 10th.

Key details include:

• An on-demand corporate presentation available from September 9th at 7:00 AM EDT
• A webcast accessible for 90 days after the event
• The presentation will also be available on Lumos Pharma's website

Investors can contact H.C. Wainwright sales representatives or Lumos Pharma's Investor Relations to schedule meetings with management during or after the conference.

AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 26th Annual Global Investment Conference being held September 9^th – 11^th in New York City. Lumos Pharma management will be present to host one-on-one meetings on Monday and Tuesday, September 9^th and 10^th.

H.C. Wainwright 26th Annual Global Investment Conference: September 9^th – 11^th

	Title:	Lumos Pharma Corporate Presentation (On-Demand)
	Date/Time:	September 9th at 7:00AM EDT
	Webcast Link:	Register here
	1x1 Meetings:	Monday-Tuesday, September 9th-10th

The presentation webcast can be downloaded at 7:00AM EDT on September 9^th and will be available for 90 days thereafter. The webcast can also be accessed on the Company’s website under Events & Presentations in the Investors & Media section. Please contact your H.C. Wainwright salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with management at the conference or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

FAQ

When is Lumos Pharma (LUMO) participating in the H.C. Wainwright Global Investment Conference?

Lumos Pharma (LUMO) is participating in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City.

What type of meetings will Lumos Pharma (LUMO) host at the conference?

Lumos Pharma (LUMO) management will host one-on-one meetings on Monday and Tuesday, September 9th and 10th, 2024.

When will Lumos Pharma's (LUMO) corporate presentation be available at the conference?

Lumos Pharma's (LUMO) on-demand corporate presentation will be available from September 9th, 2024, at 7:00 AM EDT.

How long will Lumos Pharma's (LUMO) presentation webcast be accessible?

Lumos Pharma's (LUMO) presentation webcast will be accessible for 90 days after the conference.

Where else can investors access Lumos Pharma's (LUMO) presentation from the conference?

Investors can access Lumos Pharma's (LUMO) presentation on the company's website under Events & Presentations in the Investors & Media section.